COPD activates bitter taste receptors, the target of asthma treatment

Published Date: 17 Mar 2023

Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...

Read Full News

Latest News

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

Todays Updates

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA Frank C. Sciurba, MD

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Joanna Wardlaw, MD, on Biomarkers, Repurposed Drugs, and the Future of Small Vessel Disease Treatment Marco Meglio

Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.

Collective Advocacy, Shared Priorities, and What’s Ahead at MDA 2027 Marco Meglio, Paul Melmeyer, MPP

Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.

NeuroVoices: Bruce Ovbiagele, MD, MSc, MAS, MBA, on the Future of Stroke Publishing Marco Meglio, Bruce Ovbiagele, MD, MSc, MAS, MBA

The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.

Brain Chat: Migraine: More Than Just a Headache Mitzi Joi Williams, MD

Mitzi Joi Williams, MD, is joined by Temitope Adeola, MD, and Chantale Branson, MD, to discuss migraine as a complex neurological condition, including recognizing symptoms and triggers, navigating acute and preventive treatment options, and incorporating lifestyle modifications to improve migraine management.

Why Patients Miss Dialysis Treatments, With Steven Brunelli, MD Steven Brunelli, MD

A Kidney Week 2026 survey examines why patients miss dialysis, when barriers arise, and how outreach relates to rescheduling.

Todays Updates

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA Frank C. Sciurba, MD

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Joanna Wardlaw, MD, on Biomarkers, Repurposed Drugs, and the Future of Small Vessel Disease Treatment Marco Meglio

Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.

Collective Advocacy, Shared Priorities, and What’s Ahead at MDA 2027 Marco Meglio, Paul Melmeyer, MPP

Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.

NeuroVoices: Bruce Ovbiagele, MD, MSc, MAS, MBA, on the Future of Stroke Publishing Marco Meglio, Bruce Ovbiagele, MD, MSc, MAS, MBA

The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.

Brain Chat: Migraine: More Than Just a Headache Mitzi Joi Williams, MD

Mitzi Joi Williams, MD, is joined by Temitope Adeola, MD, and Chantale Branson, MD, to discuss migraine as a complex neurological condition, including recognizing symptoms and triggers, navigating acute and preventive treatment options, and incorporating lifestyle modifications to improve migraine management.

Why Patients Miss Dialysis Treatments, With Steven Brunelli, MD Steven Brunelli, MD

A Kidney Week 2026 survey examines why patients miss dialysis, when barriers arise, and how outreach relates to rescheduling.

Latest News

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

News All Time

CHEST 2026: Day 3 Recap — 6 Headlines to Know

CHEST 2026: Day 3 Recap — 6 Headlines to Know

Why Oxygen Stigma Persists, With Mike Hess, MPH Mike Hess, MPH

On World Oxygen Day, the COPD Foundation's Mike Hess outlines the stigma, training gaps, and Medicare barriers affecting patients on supplemental oxygen.

Lower Baseline FVC Linked to Better Sarcoidosis Treatment Response Vivienne Kahlmann

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

When to Switch Biologics in Severe Asthma, With Florence Schleich, MD, PhD Florence Schleich, MD, PhD

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

CHEST 2026: Day 2 Recap — 4 Headlines to Know

CHEST 2026: Day 2 Recap — 4 Headlines to Know

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

Examining the Oral Steroid Burden in Asthma and COPD

Examining the Oral Steroid Burden in Asthma and COPD

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

Recommended News For You

TULSA Is Effective in Long-Term Prostate Cancer Control.

findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

Charting the Course: From Young Adult Leukemia Patient to Oncologist.

There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.

Recommended Articles For You

Personalized Cancer Vaccines: The Next Frontier in Precision Oncology 

Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer 

Unlocking the Secrets of Oral Cancer Staging: A New Approach to Early Detection 

Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In 18 States, alcohol exclusion laws are still in effect.

2.

According to a study, breast cancer cells work together to physically breach barriers and proliferate.

3.

Vaccine shows promise for pancreatic cancer, study finds

4.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

5.

Mezigdomide Combinations Show Promise in Multiple Myeloma

1.

The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease 

2.

AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers

3.

Everything You Need to Know About Leiomyomas: A Comprehensive Guide 

4.

Clinical Guidelines for Hematopoietic Stem Cell Niche Monitoring in Blood Disorders

5.

Erythrocyte Functional Impairment During Critical Illness: Mechanisms, Clinical Implications, and Management

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

3.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

4.

Early Warning Signs of Cancer

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot